News
In this randomized controlled trial, mepolizumab decreased the annualized rate of moderate or severe exacerbations when added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback